Using a human skin explant system Aquila is able to generate an immunological signature of the effects that immunomodulatory compounds may have when injected into human skin. This system has the potential to be manipulated for a variety of purposes.
Psoriasis is a common, chronic, relapsing/remitting, immune-mediated systemic disease affecting approximately 4% of the general population. It is characterised by lesions of the skin, typically as itchy red, scaly patches or plaques. Lesions have infiltration of immune cells in the dermis and epidermis and massively altered epidermis structure. Psoriasis is believed to result from the dysregulated interplay between keratinocytes and infiltrating immune cells, although the exact cause is unknown.
Skin lesions seen in psoriasis vary in severity between individuals from minor localized patches to complete body coverage. Around 20-30% of patients with psoriasis will develop psoriatic arthritis which affects articular joints. Current therapies for psoriasis and psoriatic arthritis are crude and ineffective, necessitating the requirement for better preclinical models for early drug development.
Aquila is developing standard and novel models in collaboration with interested parties to include:
Please contact us to find out more about our human skin explant system or Inflammatory models.